Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-12 3:36 pm Sale | 2024-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN | MFN Partners, LP | 0 0.000% | -121,384 (Position Closed) | Filing History |
| 2025-02-12 1:25 pm Purchase | 2024-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN | American Endowment Foundation | 133,026 4.910% | 133,026 (New Position) | Filing History |
| 2025-02-12 09:28 am Sale | 2024-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN | FMR LLC | 4,740 0.200% | -158,109 (-97.09%) | Filing History |
| 2024-12-06 4:05 pm Sale | 2024-11-30 | 13G | Cyclerion Therapeutics, Inc. CYCN | Slate Path Capital LP | 0 0.000% | -357,880 (Position Closed) | Filing History |
| 2024-07-12 6:17 pm Sale | 2024-07-12 | 13G | Cyclerion Therapeutics, Inc. CYCN | Artal Participations S.a r.l | 116,155 4.300% | -22,800 (-16.41%) | Filing History |
| 2024-02-14 4:05 pm Purchase | 2023-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN | TYNDALL CAPITAL PARTNERS L P | 164,429 6.700% | 42,791 (+35.18%) | Filing History |
| 2024-02-09 5:06 pm Sale | 2023-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN | Artal Participations S.a r.l | 138,955 5.700% | -1 (-0.00%) | Filing History |
| 2024-02-09 08:50 am Purchase | 2024-02-08 | 13G | Cyclerion Therapeutics, Inc. CYCN | FMR LLC | 162,849 6.660% | 162,849 (New Position) | Filing History |
| 2024-01-22 3:44 pm Purchase | 2023-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN | Slate Path Capital LP | 357,880 14.600% | 357,880 (New Position) | Filing History |
| 2023-12-05 4:00 pm Purchase | 2023-11-30 | 13D | Cyclerion Therapeutics, Inc. CYCN | Hecht Peter M | 840,899 26.900% | 322,435 (+62.19%) | Filing History |
| 2023-09-05 4:05 pm Purchase | 2023-08-23 | 13G | Cyclerion Therapeutics, Inc. CYCN | TYNDALL CAPITAL PARTNERS L P | 121,638 5.050% | 121,638 (New Position) | Filing History |
| 2023-05-23 4:00 pm Purchase | 2023-05-19 | 13D | Cyclerion Therapeutics, Inc. CYCN | Hecht Peter M | 518,464 19.990% | 518,464 (New Position) | Filing History |
| 2023-05-12 08:39 am Purchase | 2023-05-11 | 13D | Cyclerion Therapeutics, Inc. CYCN | Hecht Peter M | 518,465 19.990% | 307,482 (+145.74%) | Filing History |
| 2023-04-03 07:30 am Purchase | 2023-03-31 | 13D | Cyclerion Therapeutics, Inc. CYCN | Hecht Peter M | 210,983 9.200% | 980 (+0.47%) | Filing History |
| 2023-02-09 09:59 am Purchase | 2023-02-09 | 13G | Cyclerion Therapeutics, Inc. CYCN | FMR LLC | 171,048 7.865% | 40,178 (+30.70%) | Filing History |
| 2023-01-13 4:30 pm Unchanged | 2022-11-01 | 13G | Cyclerion Therapeutics, Inc. CYCN | Slate Path Capital LP | 357,880 16.500% | 0 (Unchanged) | Filing History |
| 2022-11-21 5:00 pm Purchase | 2022-11-20 | 13D | Cyclerion Therapeutics, Inc. CYCN | Hecht Peter M | 210,003 9.200% | 30,169 (+16.78%) | Filing History |
| 2022-10-21 5:13 pm Unchanged | 2022-10-21 | 13D | Cyclerion Therapeutics, Inc. CYCN | Slate Path Capital LP | 357,880 16.500% | 0 (Unchanged) | Filing History |
| 2022-02-11 4:41 pm Purchase | 2021-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN | Slate Path Capital LP | 357,880 16.490% | 48,077 (+15.52%) | Filing History |
| 2022-02-11 06:35 am Purchase | 2021-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN | Artal Participations S.a r.l | 138,956 6.400% | 48,077 (+52.90%) | Filing History |